-
公开(公告)号：US20240360195A1
公开(公告)日：2024-10-31
申请号：US18579283
申请日：2022-07-13
发明人： Reinhard Zeidler
IPC分类号： C07K14/705 , A61K38/00
CPC分类号： C07K14/70503 , A61K38/00 , C07K2317/14 , C07K2317/55 , C07K2317/565
摘要： The present invention relates to a novel dimer composed of a first Fab monomer and a second Fab monomer, each Fab monomer comprising a VH and a VL region, wherein two of such VH or VL regions are covalently linked by a disulfide bond between an additional non-naturally occurring cysteine residue at their respective N-termini.
-
公开(公告)号：US20240124891A1
公开(公告)日：2024-04-18
申请号：US18277558
申请日：2022-02-17
CPC分类号： C12N15/86 , A61P25/16 , C12N9/22 , C12N15/11 , C07K2319/92 , C12N2310/20 , C12N2750/14143 , C12N2800/40 , C12N2840/445
摘要： The present invention relates to CRISPR-mediated means and methods, e.g., for adjustably induction of multiple gene expression and subsequent cell reprogramming. Particularly, the CRISPR-mediated means and methods of the present invention relate to conversion of endogenous glial cells into GABAergic neurons representing an effective method for cell reprogramming.
-
公开(公告)号：US20230024301A1
公开(公告)日：2023-01-26
申请号：US17765804
申请日：2020-10-02
IPC分类号： C12N15/861 , C07K14/47 , A61P21/00
摘要： The present invention relates a vector system and a vector system for use in a method of treating a disease, each comprising a first vector and a second vector. The present invention further relates to the first vector, the second vector and a combination of the first vector and the second vector. In addition, the present invention relates to a pharmaceutical composition comprising the vector system of the invention or the combination of the invention.
-
公开(公告)号：US20220236187A1
公开(公告)日：2022-07-28
申请号：US17617190
申请日：2020-06-07
申请人： HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： Oliver BRUNS , Jakob LINGG , Martin WARMER , Shyam S. RAMAKRISHNAN , Mara SACCOMANO , Ellen SLETTEN , Emily COSCO
IPC分类号： G01N21/64
摘要： The present invention relates to systems, methods and fluorophores for real-time multicolor shortwave infrared fluorescence imaging. The systems and methods of the present invention further relate to real-time multi-color in vivo SWIR imaging systems employing high-power excitation sources in combination with state of the art InGaAs SWIR detectors and SWIR illuminated fluorophores.
-
公开(公告)号：US11161902B2
公开(公告)日：2021-11-02
申请号：US16300019
申请日：2017-05-09
摘要： In general, the present invention relates to the field of (bio-)medicine and in particular to various metabolic diseases. Specifically, the invention provides means and methods for diagnosing, monitoring and predicting the risk for developing metabolic diseases. The invention uses exosomes as biomarkers for the aforementioned purposes. Moreover, an antibody of the present invention capable of specifically recognizing tissue-specific exosomes is also provided.
-
公开(公告)号：US11149289B2
公开(公告)日：2021-10-19
申请号：US15960364
申请日：2018-04-23
发明人： Ralf Kühn
IPC分类号： C12N15/90 , A01K67/027 , C12N15/62 , C12N15/85 , C12N9/22 , C12N5/075 , C12N9/16 , C07K14/195
摘要： The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease. Also, the present invention relates to a vector comprising the nucleic acid molecule and a protein encoded by said nucleic acid molecule. Further, the invention relates to a method of modifying the genome of a eukaryotic cell and a method of producing a non-human vertebrate or mammal.
-
公开(公告)号：US20210230245A1
公开(公告)日：2021-07-29
申请号：US17048928
申请日：2019-04-17
申请人： MEDIZINISCHE HOCHSCHULE HANNOVER , HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
IPC分类号： C07K14/725 , C07K16/08 , C07K14/705 , A61K35/17 , A61P31/22
摘要： An isolated chimeric antigen receptor (CAR) polypeptide, wherein the CAR includes an extracellular antigen-binding domain, including an antibody or antibody fragment that binds to a protein encoded by a herpes virus, or to a protein complex including the protein (herpes virus antigen), wherein the herpes virus antigen is present on the surface of a human cell that is latently infected with said herpes virus and supports the lytic phase of viral replication. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of the cell in the treatment of a medical disorder associated with human herpesvirus, such as herpes virus-associated cancers, chronic active herpes virus infections or primary herpes virus infections. In preferred embodiments the herpes virus is Epstein-Barr virus (EBV) and a preferred herpes virus antigen target of the CAR is the EBV glycoprotein 350/220 (gp350/gp220).
-
公开(公告)号：US10912827B2
公开(公告)日：2021-02-09
申请号：US16069268
申请日：2017-01-12
摘要： The present invention relates to an improved recombinant vaccination vector for the treatment or vaccination against hepatitis B virus (HBV) as well as pharmaceutical compositions or vaccines comprising said recombinant vaccination vector. The present invention also relates to a recombinant vaccination vector for use in a method of vaccination against HBV, as well as kits comprising a vaccine comprising the recombinant vaccination vector.
-
公开(公告)号：US10730943B2
公开(公告)日：2020-08-04
申请号：US16112431
申请日：2018-08-24
申请人： Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH) , Deutsches Krebsforschungszentrum
IPC分类号： C07K16/10 , C07K16/28 , C12N5/0783 , C07K16/08 , A61K39/00
摘要： The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (CDRs) configured to bind a first antigen; and (b) (ba) a second set of six CDRs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from Hepatitis B virus (HBV) small surface antigen; HBV medium surface antigen; and HBV large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Also provided are compositions for use in a method of treating or preventing HBV infection and/or a condition caused by said HBV infection, said condition caused by said HBV infection being selected from liver cirrhosis and hepatocellular carcinoma.
-
公开(公告)号：US10520494B2
公开(公告)日：2019-12-31
申请号：US15126623
申请日：2015-03-26
发明人： Heiko Lickert , Adriana Migliorini , Moritz Gegg , Erik Bader
IPC分类号： C12N5/071 , G01N33/50 , G01N33/569 , C12Q1/6881 , A61K38/17 , G01N33/68
摘要： The present invention relates to the use of the biomarker Flattop (Fltp) for distinguishing mature β cells from immature progenitor β cells. The present invention further relates to a method for distinguishing a mature β cell from an immature progenitor β cell, the method comprising: determining the presence or absence of the biomarker Flattop (Fltp) in a β cell; wherein the presence of Fltp in the cell indicates that the cell is a mature β cell and wherein the absence of Fltp in the cell indicates that the cell is an immature progenitor β cell. Furthermore, the present invention relates to a method of identifying a compound suitable for differentiating immature progenitor β cells into mature β cells as well as to a method of identifying a compound suitable for preventing the de-differentiating of mature β cells.
-
-
-
-
-
-
-
-
-
搜索结果
94 条记录 (耗时 0.042 秒)
